Bremelanotide (PT-141)

Mechanism of Action

Bremelanotide (PT-141) is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors to enhance sexual desire and arousal. However, the specific molecular mechanisms underlying its therapeutic effects are not fully detailed in the available evidence.

The compound appears to work through activation of melanocortin receptor pathways, as suggested by research on "selective targeting of human melanocortin receptors" mentioned in the literature. Melanocortin receptors are G-protein coupled receptors that, when activated, can influence various physiological processes including sexual behavior through central nervous system pathways.

Bremelanotide contains D-amino acids in its structure, which may contribute to its pharmacological properties and resistance to enzymatic degradation. This structural feature is consistent with other FDA-approved therapeutic peptides that incorporate D-amino acids for enhanced stability and bioactivity.

The evidence suggests bremelanotide works centrally rather than through peripheral mechanisms, distinguishing it from other sexual dysfunction treatments. It appears to modulate neural pathways involved in sexual desire and arousal, though the precise downstream signaling cascades and neuroanatomical targets are not comprehensively described in the available literature.

Evidence Limitations: The current evidence provides limited detail about bremelanotide's specific receptor binding profiles, downstream signaling mechanisms, or the precise neural circuits involved in its therapeutic effects. More detailed mechanistic studies would be needed to fully characterize how this compound produces its clinical benefits in treating hypoactive sexual desire disorder.

This information is for educational purposes only and should not replace consultation with a healthcare provider for personalized medical advice.

Bremelanotide (PT-141) is primarily indicated for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The compound has undergone extensive clinical evaluation for this specific indication, with multiple completed Phase 2 and Phase 3 trials.

Primary Clinical Use

Hypoactive Sexual Desire Disorder in Premenopausal Women: The most well-established clinical application is for treating HSDD in premenopausal women. Two completed Phase 3 clinical trials (NCT02338960 and NCT02333071) have evaluated bremelanotide's efficacy and safety for this indication. These pivotal studies formed the basis for regulatory approval, demonstrating the compound's ability to increase sexual desire and reduce associated distress in this patient population.

Additional Areas of Investigation

Female Sexual Arousal Disorder: A Phase 2 study (NCT01382719) investigated bremelanotide's effects on both female sexual arousal disorder and HSDD, suggesting potential broader applications within female sexual dysfunction.

Potential Use in Men: Recent clinical literature has begun exploring whether bremelanotide should be considered for treating sexual arousal and desire disorders in men, though this remains investigational and is not currently an approved indication.

Cancer-Related Sexual Dysfunction: Emerging evidence suggests potential applications for managing sexual health concerns in cancer patients, particularly those with breast and gynecologic cancers experiencing treatment-related sexual dysfunction from endocrine therapies.

Mechanism and Therapeutic Context

Bremelanotide works through melanocortin receptor pathways, representing a novel therapeutic approach distinct from traditional hormonal treatments for sexual dysfunction. The compound is part of a broader category of therapeutic peptides being investigated for various applications in aging and sexual health.

Evidence Limitations

While the primary indication for HSDD in premenopausal women is well-supported by Phase 3 trial data, evidence for other potential applications remains limited to early-phase studies or theoretical considerations. The clinical evidence for use in men or specific cancer populations requires further investigation.

This information is for educational purposes only and should not replace consultation with a healthcare provider for individual medical decisions.

Safety Profile of Bremelanotide (PT-141)

Evidence Limitation: The provided evidence contains limited specific safety data for bremelanotide. The available information primarily consists of study titles and clinical trial registrations without detailed safety results or adverse event profiles.

Known Side Effects

Based on the available evidence, specific side effect data for bremelanotide is not detailed in the provided materials. The completed Phase 2 and Phase 3 clinical trials (NCT02338960, NCT02333071, NCT01382719) evaluated safety alongside efficacy in premenopausal women, but the actual safety outcomes are not specified in the evidence provided.

Evidence gap: Comprehensive side effect profiles, frequency of adverse events, and severity classifications are not available in the current evidence base.

Contraindications

The provided evidence does not contain specific contraindication information for bremelanotide.

Evidence gap: Absolute and relative contraindications are not detailed in the available materials.

Drug Interactions

No drug interaction data is provided in the available evidence.

Evidence gap: Potential interactions with other medications, including mechanism-based interactions or contraindicated combinations, are not documented in the provided sources.

Special Populations

The clinical trial evidence focuses specifically on premenopausal women with hypoactive sexual desire disorder and/or female sexual arousal disorder. One source mentions consideration for use in men, but safety data for this population is not provided.

Populations with limited evidence:

• Men (safety profile not established in provided evidence)
• Postmenopausal women
• Pregnant or breastfeeding women
• Pediatric populations
• Elderly patients
• Patients with hepatic or renal impairment

Clinical Considerations

The available evidence suggests bremelanotide has been studied in controlled clinical settings through Phase 2 and 3 trials, indicating it has undergone formal safety evaluation. However, the specific results of these safety assessments are not available in the provided materials.

Disclaimer: This safety information is based on limited evidence. Healthcare providers should consult complete prescribing information and conduct thorough patient assessments before considering bremelanotide therapy. Patients should discuss potential risks and benefits with their healthcare provider.

Evidence quality: The safety profile presented here is incomplete due to insufficient detailed safety data in the provided evidence base. More comprehensive safety information would be needed for clinical decision-making.

Research Papers and Clinical Trials

The research on bremelanotide (PT-141) includes several completed clinical trials and ongoing academic research, though detailed study results are limited in the available evidence.

Clinical Trials

Two major Phase 3 clinical trials (NCT02338960 and NCT02333071) have been completed evaluating bremelanotide's efficacy and safety in premenopausal women with hypoactive sexual desire disorder (HSDD). An earlier Phase 2 trial (NCT01382719) examined the drug's effects in premenopausal women with both female sexual arousal disorder and HSDD. While these trials are marked as completed, specific results, sample sizes, and detailed outcomes are not provided in the available evidence.

Academic Research

Recent academic literature suggests continued interest in bremelanotide's therapeutic applications. A 2026 systematic review examined clinical trial evidence for emerging pharmacological therapies for HSDD in women, likely including bremelanotide among the treatments analyzed. Another 2026 paper specifically questioned whether bremelanotide should be considered for treating sexual arousal and desire disorders in men, suggesting research interest beyond its current approved indication.

Additional research has explored bremelanotide in specialized contexts, including strategies for treating sexual health concerns after breast and gynecologic cancer, and practical approaches for managing sexual symptoms in breast cancer patients on endocrine therapies.

Research Gaps

The available evidence shows that while clinical trials have been completed and academic interest continues, detailed study methodologies, sample sizes, and specific clinical outcomes are not readily accessible in the current literature summaries. More comprehensive data from the completed trials would be needed to fully assess the clinical evidence base.

Note: This synthesis is based on limited available evidence. Consult healthcare providers for current clinical recommendations and detailed study results.

Protocols

Based on the available literature, specific dosing and administration protocols for bremelanotide are not detailed in the provided evidence. The clinical trial data shows that bremelanotide has been studied in multiple Phase 2 and Phase 3 completed trials for hypoactive sexual desire disorder in premenopausal women, but the exact protocols used in these studies are not specified in the available abstracts.

The evidence indicates that bremelanotide has been evaluated for:

• Hypoactive sexual desire disorder in premenopausal women (multiple Phase 3 trials)
• Female sexual arousal disorder and/or hypoactive sexual desire disorder (Phase 2 trial)

However, the specific dosing regimens, administration routes, frequency of dosing, or treatment duration protocols are not provided in the available study summaries.

One review article discusses whether bremelanotide should be considered for sexual arousal and desire disorders in men, suggesting ongoing research into its potential applications beyond the established indication in women, but again without specific protocol details.

The limited evidence available does not provide sufficient detail to describe typical dosing and administration protocols from the published literature.

Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Any decisions regarding bremelanotide therapy should be made in consultation with a qualified healthcare provider who can assess individual medical needs and circumstances.

Outcomes

The evidence for bremelanotide (PT-141) outcomes is primarily based on completed Phase 2 and Phase 3 clinical trials in premenopausal women with hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder, though detailed efficacy data from these trials is not available in the provided evidence.

Primary Clinical Applications:
Three completed clinical trials specifically evaluated bremelanotide in premenopausal women with HSDD, including two Phase 3 studies (NCT02338960, NCT02333071) and one Phase 2 study that also included women with female sexual arousal disorder (NCT01382719). However, the specific outcome measures, effect sizes, and statistical significance of results from these trials are not detailed in the available evidence.

Strength of Evidence:
The evidence base appears limited to completed clinical trials in female sexual dysfunction, with the provided literature focusing more on review articles and broader therapeutic considerations rather than presenting specific efficacy data. While multiple completed Phase 3 trials suggest regulatory-grade evidence exists, the actual measurable outcomes, biomarker changes, or symptom improvement metrics are not quantified in the available sources.

Emerging Applications:
Recent literature suggests potential consideration of bremelanotide for sexual arousal and desire disorders in men, though specific outcome data for this application is not provided in the evidence. The compound is also mentioned in the context of therapeutic peptides for aging-related conditions, but again without specific efficacy metrics.

Evidence Limitations:
The available evidence does not include published results from the completed clinical trials, making it impossible to report specific measurable outcomes, effect sizes, response rates, or biomarker changes. The strength of evidence for bremelanotide's clinical efficacy cannot be adequately assessed based solely on trial registry information and review articles without access to the primary efficacy data.

This summary is for informational purposes only and should not replace consultation with a healthcare provider for personalized medical advice.